Testing effectiveness (Phase 2)Looking for participantsNCT07330037
What this trial is testing
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 41